Dr. James Chen led them to a home office that was clearly where he spent a significant portion of his time. The walls were lined with pharmaceutical research papers, regulatory documents, and what appeared to be years of accumulated notes on various medications and treatments.
"I am the director of research at HealthPlus Pharmaceuticals," Dr. Chen began, pulling up files on his computer. "HealthPlus is one of the most prestigious pharmaceutical companies in the region, with a research program that has contributed to dozens of major medical breakthroughs. But six months ago, Marcus Vane acquired a controlling interest in the company through a series of complex financial transactions that were technically legal but ethically questionable."
He pulled up a series of documents showing Vane's
